Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 696 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis, Chronic Clear all

Conditions: Hepatitis C Virus
Interventions: ribavirin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Hepatitis B
Interventions: hepatitis B immune globulin (HBIg), Pegylated interferon alfa (pegIFN); Biological · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, Chronic
Interventions: GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 18
States / cities: Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more

Conditions: Chronic Hepatitis C
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Durham, North Carolina • Rocky Mount, North Carolina

Conditions: Hepatitis C
Interventions: Interleukin 2, Ribavirin, Pegylated Interferon Alpha, Inteleukin-2, Ribavirin + Pegylated interferon-alpha; Biological · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Hepatitis B
Interventions: Adefovir Dipivoxil for oral suspension, 2 mg/mL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Foster City, California

Conditions: HIV, Hepatitis C, Chronic, HCV Coinfection
Interventions: Not listed
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatitis C
Interventions: XTL 6865; Drug
Lead sponsor: XTL Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Indianapolis, Indiana • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Patient Adherence, Chronic Hepatitis C, Alcohol-related Disorders
Interventions: VBMI; Behavioral
Lead sponsor: G.V. (Sonny) Montgomery VA Medical Center; Federal
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Chronic Hepatitis C
Interventions: LDV/SOF FDC; Drug
Lead sponsor: Peter J. Ruane, M.D., Inc.; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatitis C, Chronic
Interventions: Simeprevir, Daclatasvir, Sofosbuvir; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions: Faldaprevir, TD-6450, Ribavirin; Drug
Lead sponsor: Trek Therapeutics, PBC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Coronado, California • Bradenton, Florida • Germantown, Tennessee

Conditions: Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 8,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1992
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 26
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 19 more

Conditions: Chronic Hepatitis B
Interventions: Tenofovir DF, FTC, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: Hepatitis C, Chronic
Interventions: eltrombopag, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 47
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 40 more

Conditions: Chronic Hepatitis C
Interventions: Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin; Drug · Biological
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 10
States / cities: Palo Alto, California • Stanford, California • New Haven, Connecticut + 7 more

Conditions: Hepatitis B, Chronic
Interventions: Tenofovir Alafenamide; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Palo Alto, California • San Jose, California

Conditions: Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
Interventions: PEG-Interferon a-2b + Ribavirin; Drug
Lead sponsor: Hepatitis Resource Network; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C Virus
Interventions: Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin, Telaprevir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 28
States / cities: Birmingham, Alabama • Anaheim, California • Garden Grove, California + 20 more

Conditions: Hepatitis B, Chronic
Interventions: peginterferon alfa-2a [Pegasys], tenofovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Hepatitis B, Cirrhosis
Interventions: LdT (Telbivudine) and lamivudine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV, Hepatitis C
Interventions: Motivational interviewing, Educational intervention; Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 851 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Hepatitis C Infection
Interventions: Valacyclovir, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Jackson, Mississippi

Search by objective public record fields.

Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection

Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B

Dose Ranging of GSK2336805 in Combination Therapy

Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B

The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Evaluation of Patients With Liver Disease

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.

Chronic Hepatitis Intervention Project for Drug Users

Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)